Welcome to our dedicated page for Cosmo Pharmaceuticals Nv news (Ticker: CMOPF), a resource for investors and traders seeking the latest updates and insights on Cosmo Pharmaceuticals Nv stock.
News for COSMO PHARMA NV ORD (CMOPF) centers on the activities of Cosmo Pharmaceuticals N.V., a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and CDMO. Company announcements highlight how Cosmo executes its Vision 2030 strategy, emphasizing recurring revenue growth, AI-enabled medical technologies, and global expansion of its dermatology and GI franchises.
Investors following CMOPF-related news can expect updates on GI Genius™ and the ColonPRO / ColonPRO EU AI platforms for colonoscopy, including regulatory milestones such as CE certification in Europe and clinical evidence from international trials. News also covers the evolution of GI Genius™ into a scalable AI platform, deployment across clinical sites, and initiatives such as spatial-computing usability studies that integrate AI endoscopy modules with advanced visualization devices.
Dermatology news frequently focuses on Winlevi® and clascoterone 5% topical solution. Releases describe new regulatory approvals for Winlevi® in regions including the European Union, South Korea, Brazil, and other territories, as well as commercialization through partners. For clascoterone 5% solution in male androgenetic alopecia, news has detailed Phase III topline results, patient-reported outcomes, safety data, and plans for regulatory submissions in the United States and Europe.
Additional updates include progress in clinical programs for bile acid diarrhea and distal ulcerative colitis, renewal of manufacturing agreements such as the multi-year supply arrangement with Takeda for Mesalazine MMX 1200 mg, and financial communications on revenue mix, recurring revenue trends, and cash position. Bookmark this page to monitor regulatory events, clinical milestones, partnership announcements, and financial disclosures that relate to CMOPF and Cosmo Pharmaceuticals’ multi-platform growth strategy.
Cosmo (OTC:CMOPF) has convened its Ordinary Annual General Meeting for 10 April 2026 in Amsterdam. Key agenda items include the Board report for 2025, appropriation of full-year 2025 results, a proposed distribution of €2.10 per share, a corporate name change to Cosmo N.V., director reappointments, adoption of remuneration policy, and authorisations to issue new ordinary and preferred shares.
Complete convening notice, explanatory notes and proxy, plus the Annual Report 2025 and ESG Report 2025, are available on the company website.
Cosmo Pharmaceuticals (OTC: CMOPF) reported FY2025 total revenue €104.2M with recurring revenues €88.1M (+15% YoY, 85% of total), EBITDA €9.5M (above guidance), cash, equivalents and investments €128.3M and no financial debt. The Board proposes a €2.10 dividend. 2026 guidance: recurring revenues €98–102M, total revenues €105–110M, EBITDA €10.5–13.5M and year-end cash ~€200M.
Cosmo (OTC:CMOPF) announced a strategic R&D collaboration with Amsterdam UMC and Eindhoven University of Technology to develop and clinically validate an AI-based computer-aided detection (CADe) system for early neoplasia in Barrett's esophagus.
The program will curate large imaging datasets, train AI algorithms, run structured clinical validation, and pursue industrialization and regulatory pathways for integration into the GI Genius platform.
Cosmo Pharmaceuticals (OTC:CMOPF) announced management will attend three investor conferences in March–May 2026 with scheduled one-on-one investor meetings.
Key dates: UBS European Healthcare Conference (London) on 4 March 2026; Jefferies Biotech Summit (Miami) on 11 March 2026; TP ICAP Healthcare Conference (Paris) on 7 May 2026. Investors may request meetings via investor.relations@cosmohc.com.
Cosmo Pharmaceuticals (OTC:CMOPF) completed a private placement of 937,086 treasury shares to Capital Group's SMALLCAP World Fund on February 3, 2026, representing ~5.3% of outstanding shares. The sale used existing treasury shares and therefore does not dilute existing shareholders; shares are fungible and rank pari passu. Cosmo said the transaction strengthens its shareholder base, enhances financial flexibility, and supports investment in MedTech AI, dermatology, gastroenterology, and CDMO. Cosmo will file required major shareholding notifications with SIX Swiss Exchange.
Summary not available.
Cosmo (OTC:CMOPF) reported preliminary unaudited 2025 results: €104 million revenue at the guidance midpoint (recurring revenue €88m, project €16m) and year-end cash, equivalents and short-term investments above €128 million with zero debt. Recurring revenues rose €12m, ~15% YoY. EBITDA landed at the upper end of guidance (€5.5–7.5m), indicating operating leverage as scale builds. Key commercial and clinical milestones include European approval for ColonPRO, GI Genius Module 300 rollout and an Apple Vision Pro usability study (first patient Dec 2025), Winlevi global approvals and planned European launches H1 2026, and a Clascoterone 12-month safety readout expected spring 2026.
Cosmo (OTC:CMOPF) reported topline Phase III results for clascoterone 5% topical solution in male androgenetic alopecia from two identically designed studies (total 1,465 patients) with statistically significant Target-Area Hair Count (TAHC) improvements of 5.39x (539%) and 1.68x (168%) versus vehicle.
Patient-reported outcomes were significant combined, safety and tolerability were comparable to vehicle, and Cosmo plans parallel US and EU regulatory submissions after completing a 12-month safety follow-up expected in spring 2026. Patent protection is stated through 2036 and the U.S. market opportunity was estimated above $20B.
Cosmo (OTC:CMOPF) announced that Brazil's ANVISA approved Winlevi (clascoterone) cream 1% for acne vulgaris in patients aged 12 years and older on November 14, 2025. The approval expands Winlevi availability to one of Latin America's largest dermatology markets and, together with Mexico, brings access to over 50% of the Latin American population. Sun Pharmaceutical will commercially launch Winlevi in Brazil. This marks the 13th territory where Winlevi has regulatory approval worldwide.
Winlevi is a first‑in‑class topical androgen receptor inhibitor that acts locally on sebaceous glands without systemic hormonal effects.
Cosmo Pharmaceuticals (OTC: CMOPF) announced ESG progress on November 11, 2025, reporting an upgraded S&P Global Corporate Sustainability Assessment score at the 67th percentile, up from last year’s 55th percentile. Cosmo SpA, the Group’s Italian manufacturing unit, earned an EcoVadis Bronze Medal with a 64/100 score and a ranking above 71% of rated companies. The company said it has partnered with EcoVadis to assess suppliers on environmental, social, ethical, and procurement criteria to boost supply-chain transparency and risk management. Cosmo affirmed alignment with TCFD and CSRD and plans to publish its 2025 ESG Report in early March 2026.